Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23224027 | 0.92 | SLC10A1 (0.52) | SLC10A1 | |
| SCHEMBL23223844 | 0.92 | SLC10A1 (0.56) | SLC10A1 | |
| SCHEMBL21810366 | 0.91 | SLC10A1 (0.51) | SLC10A1 | |
| SCHEMBL23223962 | 0.89 | SLC10A1 (0.52) | SLC10A1 | |
| SCHEMBL24571115 | 0.89 | SLC10A1 (0.57) | SLC10A1 | |
| SCHEMBL21378225 | 0.89 | SLC10A1 (0.52) | SLC10A1 | |
| SCHEMBL30397357 | 0.89 | SLC10A1 (0.52) | SLC10A1 | |
| SCHEMBL22307244 | 0.88 | SLC10A1 (0.56) | SLC10A1 | |
| SCHEMBL30382190 | 0.88 | SLC10A1 (0.56) | SLC10A1 | |
| SCHEMBL21296659 | 0.87 | SLC10A1 (0.61) | SLC10A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| CN-111788204-B | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| EP-3805223-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-04-14 | — | — | EP | disclosed |
| EP-3759109-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-111788204-A | Substituted pyrrolizine compounds as inhibitors of HBV replication | 吉利德科学公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2019165374-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147429-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-11420974-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
| US-20220204510-A1 | 2,3-DIHYDRO-1H-PYRROLIZINE-7-FORMAMIDE DERIVATIVE AND APPLICATION THEREOF | DPYD, EIF2AK2, INF2 | SLC10A1 76/4885 |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | SLC10A1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.